I'm very new to this forum so I tried my best to ask an appropriate question so forgive me if this is still too specific :)
My father w/ staged 4 NSCLC (after undergoing tumor resection, chemotherapy, radiation to mets site) was newly dx with brain mets (3 sites) through MRI. The thing is, his tumors in the lungs and adrenal glands (metastatic site) were considered "well-controlled" for the past 10 cycles of Keytruda he has received.
However, would the newly-found brain mets while being on Keytruda considered as "disease progression" and resistance to the drug? Or is brain mets normally locally treated while patients continue receiving Keytruda?
Is there a place I can find the guideline for some cases similar to him?
*A note is that since he was doing "well" on Keytruda, the oncologist decreased the dosage from 150mg to 100mg for the past 2 times.